Preimplantation Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Preimplantation Genetic Testing Market Trends and Insights

Rising Maternal Age & Infertility Prevalence

Chromosomal abnormality risk rises sharply after age 35, pushing demand for aneuploidy screening in the preimplantation genetic testing market. Asia-Pacific recorded significant increases in secondary infertility between 1990 and 2021, mirroring trends long observed in North America and Western Europe. Health systems now bundle genetic counseling with in-vitro fertilization (IVF) packages, positioning PGT-A as standard of care for patients with recurrent pregnancy loss. This clinical normalization creates stable, long-cycle revenue for testing laboratories and reagent suppliers. As average maternal age edges higher in emerging economies, the addressable population widens, sustaining long-term growth momentum.

Rapid Adoption of NGS-Based PGT Platforms

NGS delivers comprehensive chromosome coverage at lower per-sample cost than legacy fluorescence in situ hybridization. BGI Genomics' DNBSEQ-G99 platform cut sequencing time to 3 hours in 2024, raising daily throughput for IVF labs. Simultaneous detection of aneuploidy, structural variants, and monogenic disorders on a single flow cell simplifies laboratory workflows, shortening result delivery from days to hours. Falling read costs allow clinics to offer bundled PGT panels, fostering wider patient acceptance despite persistent out-of-pocket payments. As reimbursement frameworks mature, NGS penetration is expected to deepen across mid-tier centers that previously relied on outsourced cytogenetic testing.

Expanding Global Network of Fertility Clinics & IVF Cycles

Organized clinic chains now capture nearly 40% of IVF cycles in India, up from a negligible base a decade ago. Similar franchising models are scaling rapidly in Indonesia, Vietnam, and the Gulf states. Chain ownership standardizes quality metrics, accelerates technology roll-outs, and permits volume-based reagent pricing. Government-backed medical-tourism programs in Malaysia and Thailand further enlarge the preimplantation genetic testing market by drawing cross-border patients seeking lower procedural costs. Network effects thus reinforce PGT adoption as new sites replicate proven protocols from flagship facilities.

Employer-Funded Fertility Benefits Covering PGT

Large US employers increasingly include three IVF cycles plus genetic testing within health-benefit packages. California Senate Bill 729 mandates coverage of up to three IVF cycles, including PGT, beginning in 2025. Federal employee health plans now reimburse unlimited cycles at selected centers, accelerating utilization among government workers ^{[1]Source: United States Office of Personnel Management, “2025 FEHB IVF Coverage Expansion,” opm.gov} . Similar benefit schemes are emerging in France and the Netherlands, compressing the financial barrier to PGT and stimulating near-term procedural volumes, particularly in corporate urban centers.

Procedure & Instrumentation Cost Barrier

Testing fees of USD 350-500 per embryo and IVF cycle costs above USD 24,000 in California place combined expenses beyond reach for many patients. Although consumable prices are falling, capital outlays for sequencers still deter smaller clinics. Gradual price erosion, competitive reagent sourcing, and payer mandates are expected to lift PGT penetration from today’s 5-6% of IVF cycles to about 25% by 2030. Until then, market growth in developing regions will hinge on government subsidies and tiered pricing models.

Ethical, Religious & Legal Controversies

Debate around polygenic risk score testing (PGT-P) and elective gender selection creates patchwork regulations. Singapore's Bioethics Advisory Committee is evaluating guidelines for PGT-P, delaying commercial launch until 2026. In parts of the Middle East, religious authorities restrict embryo manipulation, limiting test scope to life-threatening conditions. Mosaic embryo transfer remains contentious, with recent studies indicating live-birth rates comparable to euploid embryos but no consensus on reporting standards. These uncertainties temper immediate uptake in otherwise receptive markets.

Segment Analysis

By Test Type: Aneuploidy Screening Sustains Volume Leadership

Aneuploidy screening accounted for 46.54% of preimplantation genetic testing market share in 2024, underscoring its role in miscarriage prevention. Demand is reinforced by rising maternal age and payer acceptance of PGT-A for repeated IVF failure. The preimplantation genetic testing market size for non-invasive PGT is projected to climb at a 10.35% CAGR to 2030, reflecting rapid clinical validation and patient preference. Adjacent segments such as monogenic disorder testing serve smaller but high-acuity cohorts, while structural rearrangement analysis addresses translocation carriers representing 2-5% of infertile couples.

Convergence toward multi-analyte assays allows labs to bundle aneuploidy, monogenic, and structural screening into one NGS run, curbing reagent overhead. Whole-genome sequencing offerings, such as GenEmbryomics’ Panacea GenomeScreen that scans 3,200 genes, illustrate the shift toward comprehensive embryo profiling. As quality metrics rise, clinics report lower cycle cancellations, bolstering revenue predictability for testing suppliers.

Note: Segment shares of all individual segments available upon report purchase

By Technology: NGS Dominance Meets AI-Driven Imaging Upside

NGS contributed 54.34% of 2024 revenue and remains the analytical backbone for PGT workflows. Oxford Nanopore’s PromethION 2 Integrated puts 290 Gb of throughput on a benchtop unit, enabling same-day turnaround for medium-volume labs. AI-assisted imaging ranks as the fastest-growing technology at 10.93% CAGR, offering non-invasive viability scoring that complements genetic data. Polymerase chain reaction and fluorescence in situ hybridization persist where targeted probes suffice, but their share is shrinking as reagent cost curves favor NGS.

Cross-platform convergence is gathering pace: some vendors integrate live-cell imaging outputs with genetic readouts to present composite embryo quality indices. Long-read sequencing addresses complex genomic regions that short-read platforms miss, a benefit for polygenic score calculation. As regulatory guidance for AI software matures, imaging solutions are expected to move from decision-support to fully autonomous triage tools, trimming lab workload.

By Product Category: Software Outpaces Hardware Capex

Consumables and reagents captured 61.23% of 2024 revenue due to their recurring nature in every test cycle. Yet software and bioinformatics services are expanding at 11.55% CAGR, reflecting escalating data volumes and clinician demand for interpretive dashboards. Instruments generate a stable installed base but face longer replacement cycles. Nucleus Genomics’ 2025 release enables evaluation of up to 20 embryos against 900 hereditary conditions, highlighting software’s role in scaling complex analytics.

Cloud deployment is standardizing; smaller labs can now upload raw FASTQ files for centralized analysis, circumventing on-site compute requirements. Vendor-agnostic platforms are emerging, allowing clinics to mix sequencer brands without losing workflow coherence. Service bundling—sequencing, analytics, reporting—simplifies procurement for clinics and secures long-term revenue for vendors.

Note: Segment shares of all individual segments available upon report purchase

By End User: Clinic Consolidation Boosts PGT Uptake

Fertility clinics controlled 67.34% of 2024 revenue and show the fastest growth at 12.20% CAGR as networks proliferate across Asia-Pacific and Latin America. Consolidated chains negotiate bulk reagent pricing and adopt uniform electronic medical records that integrate genetic reports. Hospitals represent a secondary channel, often outsourcing complex analytics but leveraging existing lab infrastructure for sample prep. Academic institutes anchor R&D, validating new methods and training embryologists who later migrate to private clinics.

As chains scale past 30-40 centers, they internalize genetic labs to protect margin and turnaround times. Instrument vendors respond with modular sequencers sized for 200-400 samples per week, matching chain throughput profiles. In parallel, national health systems in Japan and South Korea are adding fertility centers within teaching hospitals, widening access to PGT under subsidized fee schedules.

Geography Analysis

North America led with 41.23% revenue in 2024, propelled by employer coverage and state mandates that include PGT within IVF packages. The preimplantation genetic testing market size in the region is expected to stabilize at mid-single-digit growth as penetration nears saturation among privately insured couples. FDA draft guidance on AI-enabled software, issued in 2025, offers a defined pathway for algorithm validation, encouraging clinic adoption of decision-support tools^{[2]Source: FDA, “Marketing Submission Recommendations for AI-Enabled Device Software Functions,” fda.gov} . Though growth decelerates, high average selling prices and broad test menus preserve attractive margins.

Asia-Pacific is the fastest-growing territory at 12.89% CAGR through 2030. Urbanization, delayed marriage, and pollution-related infertility bolster cycle volumes. India alone opens more than 60 new IVF centers annually, while China’s three-child policy fuels government incentives for assisted reproduction. Local champions like BGI Genomics supply cost-optimized NGS kits, closing the affordability gap and expanding the preimplantation genetic testing market. Rising medical tourism to Thailand and Malaysia further diversifies demand as international patients seek competitively priced comprehensive testing.

Europe offers steady mid-single-digit growth underpinned by cross-border reproductive care. Harmonized EU device regulations simplify sequencer imports and software certification. Clinics in Prague, Barcelona, and Athens attract patients from higher-cost Northern Europe, raising utilization of bundled PGT packages that include aneuploidy and monogenic panels. Public health insurers in France and Germany cover defined indications such as recurrent miscarriage, ensuring baseline demand. Ethical oversight remains stringent, moderating uptake of polygenic testing until formal guidance is issued.